HRP-Protector – for easy and safe long-term storage of HRP conjugates
HRP-Protector is a long-term stabilizer for horseradish peroxidase (HRP) coupled to antibodies or Neutravidin/Streptavidin.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Evotec bags US$23.8m to fight tuberculosis
The Bill & Melinda Gates Foundation has granted Evotec SE $23.8m to identify the best drug combos to fight tuberculosis.
How lungs trigger innate lymphoid cell dynamics
The cells’ surrounding structures play an important role as cues from the immune system in guiding their motility and behaviour, researchers from the UK and the US report.
Researchers find clue to Parkinson’s gene therapy
An enzyme that clears out alpha-synuclein from neurons may counteract Parkinson’s Disease, report researchers from ETH Zürich and Novartis.
Chikungunya vaccine developer Themis bags $21m
Under a partnering ageement with CEPI, Themis Bioscience will receive $21m to push pivotal testing of MV-CHIK, its Chikungunya vaccine candidate.
Genetically modified fungus stops malaria mosquitoes
A fungus that produces an insecticide can stop the spread of Anopheles mosquito, which causes malaria.
Abacus Medicine postpones IPO
European pharmaceutical parallel trade company Abacus Medicine A/S has postponed its planned Initial Public Offering (IPO), due to "unfavourable market environment".
Make leukaemia therapy safer
A Belgian-British-Australian research team has created a safer version of a therapy that combats the aggressive form of a blood cancer called acute lymphoblastic leukemia (ALL) while avoiding toxicity.
Nanobiotix spins out Curadigm
Cancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
Most expensive gene therapy globally approved
The FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dose.